DENTSPLY SIRONA (NASDAQ:XRAY) Director Sells $915,708.00 in Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Gregory Lucier sold 82,200 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $11.14, for a total transaction of $915,708.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

DENTSPLY SIRONA Trading Down 0.3%

Shares of NASDAQ:XRAY opened at $11.57 on Friday. The company has a debt-to-equity ratio of 1.36, a quick ratio of 0.99 and a current ratio of 1.47. The stock has a market capitalization of $2.31 billion, a price-to-earnings ratio of -2.62, a PEG ratio of 0.85 and a beta of 1.01. DENTSPLY SIRONA Inc. has a 1-year low of $9.85 and a 1-year high of $20.59. The company has a 50 day moving average price of $11.75 and a 200 day moving average price of $13.77.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.08). The company had revenue of $904.00 million during the quarter, compared to the consensus estimate of $900.33 million. DENTSPLY SIRONA had a negative net margin of 24.34% and a positive return on equity of 17.10%. DENTSPLY SIRONA’s quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.50 EPS. DENTSPLY SIRONA has set its FY 2025 guidance at 1.600-1.600 EPS. On average, research analysts anticipate that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on XRAY shares. Evercore ISI dropped their price target on DENTSPLY SIRONA from $17.00 to $13.00 and set an “in-line” rating on the stock in a research note on Wednesday, October 8th. Zacks Research downgraded shares of DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a research report on Monday, November 10th. Wall Street Zen downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research report on Saturday, October 18th. Barclays started coverage on shares of DENTSPLY SIRONA in a research note on Monday. They issued an “underweight” rating and a $12.00 price objective for the company. Finally, Mizuho set a $13.00 target price on DENTSPLY SIRONA in a report on Friday, November 7th. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $15.77.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XRAY. AQR Capital Management LLC lifted its holdings in shares of DENTSPLY SIRONA by 109.8% during the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after buying an additional 6,970,086 shares during the last quarter. Armistice Capital LLC raised its position in DENTSPLY SIRONA by 1,044.0% during the third quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after acquiring an additional 5,234,587 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in DENTSPLY SIRONA by 662.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after acquiring an additional 4,003,606 shares during the last quarter. Norges Bank bought a new stake in DENTSPLY SIRONA in the second quarter worth approximately $39,700,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after purchasing an additional 2,172,343 shares during the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.